Regression of Iris Neovascularization after Subconjunctival Injection of Bevacizumab.
10.3341/kjo.2013.27.4.299
- Author:
Na Kyung RYOO
1
;
Eun Ji LEE
;
Tae Woo KIM
Author Information
1. Department of Ophthalmology, Seoul National University Hospital, Seoul, Korea.
- Publication Type:Case Reports ; Research Support, Non-U.S. Gov't
- Keywords:
Bevacizumab;
Neovascular glaucoma;
Subconjunctival injection
- MeSH:
Adult;
Angiogenesis Inhibitors/*administration & dosage;
Antibodies, Monoclonal, Humanized/*administration & dosage;
*Conjunctiva;
Glaucoma, Neovascular/*drug therapy;
Humans;
Injections, Intraocular;
Iris Diseases/*drug therapy;
Male;
Middle Aged;
Treatment Outcome
- From:Korean Journal of Ophthalmology
2013;27(4):299-303
- CountryRepublic of Korea
- Language:English
-
Abstract:
To describe three cases of neovascular glaucoma (NVG) where iris or angle neovascularization regressed remarkably after subconjunctival bevacizumab injections used as the initial treatment before pan retinal photocoagulation (PRP) and/or filtering surgery. Three consecutive NVG patients whose intraocular pressure (IOP) was not controlled with maximal medication were offered an off-label subconjunctival injection of bevacizumab (2.5-3.75 mg/0.1-0.15 mL, Avastin). Bevacizumab was injected into the subconjunctival space close to the corneal limbus in two or three quadrants using a 26-gauge needle. Serial anterior segment photographs were taken before and after the injection. Following subconjunctival injection of bevacizumab, iris or angle neovascularization regressed rapidly within several days. Such regression was accompanied by lowering of IOP in all three cases. The patients underwent subsequent PRP and/or filtering surgery, and the IOP was further stabilized. Our cases demonstrate that subconjunctival bevacizumab injection can be potentially useful as an initial treatment in NVG patients before laser or surgical treatment.
